m-17

Pomalidomide-5-OH is the primary active metabolite of pomalidomide. Pomalidomide-5-OH acts as a ligand for the E3 ubiquitin ligase cereblon (CRBN) and can be used to recruit the cereblon protein. Pomalidomide-5-OH can be linked to a protein ligand via a linker to form a PROTAC.

Anti-Mouse CD11a/LFA-1α Antibody (M17/4) is a rat IgG2a kappa monoclonal antibody specifically targeting CD11a/LFA-1α in mouse models. The recommended isotype control for this antibody is 'Rat IgG2a kappa, Isotype Control'.

AM-1714 is a reasonable selective agonist for the peripheral cannabinoid receptor CB2. In animal studies, it has been shown to have analgesic and anti-abnormal pain effects.

MBM-17 is a potent inhibitor of NIMA-related kinase 2 (Nek2,IC50 of 3 nM). It effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis.

MBM-17S, a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 3 nM, effectively inhibits cancer cell proliferation by inducing cell cycle arrest and apoptosis. It demonstrates antitumor activities without evident toxicity to mice.

YM-17690 is a non-analogous leukotriene agonist.

OM-1700 is a potent inhibitor of tankyrase, acting on tankyrase 1 (IC50: 127 nM) and tankyrase 2 (IC50: 14 nM). OM-1700 inhibits the growth of colon cancer cell lines and inhibits COLO 320DM cells (GI50: 650 nM).

YM-1758735 is an antagonist.

CM-1758, a histone deacetylase (HDAC) inhibitor, inhibits tumor growth in vivo and induces acetylation of non-histone proteins in acute myeloid leukemia cells [1].

SM-17 is a humanized monoclonal antibody inhibitor that targets interleukin 25 (IL-25) and interleukin 17 receptor B (IL17RB). It holds potential for research in immune system disorders.

M 17 is a bioactive chemical.

C-176 (STING inhibitor 1) is a STING inhibitor with selectivity and blood-brain barrier permeability. C-176 inhibits STING-mediated IFNβ production and possesses anti-inflammatory activity.

H-151 is a highly potent and selective STING antagonist. H-151 covalently binds to Cys91 of STING and inhibits palmitoylation of Cys91, thereby inhibiting STING activity. H-151 can be used in the study of autoinflammatory diseases in vivo and ex vivo.

Vadimezan (DMXAA) is a vascular disrupting agent, a murine STING agonist, and an inducer of cytokines such as type I IFN. Vadimezan has antitumor activity and induces a rapid cessation of blood flow in tumors without affecting blood flow in normal tissues.

Omaveloxolone (RTA-408) (RTA-408) is a synthetic triterpenoid that activates the cytoprotective transcription factor Nrf2 and inhibits NF-κB signaling. Phase 2.

MSA-2 is an orally available non-nucleotide STING agonist. The non-covalent dimer of MSA-2 binds to STING with nanomolar affinity. It shows anti-tumor activity in syngeneic mouse tumor models, synergizes with anti-PD-1, stimulates tumor secretion of interferon-β, induces tumor regression, and has long-lasting anti-tumor immunity. [3]

SN-011 (GUN35901) is a STING inhibitor, which inhibited the activation of the STING signal pathway and to prevent or treat a STING- mediated disease. It is a demethyl analogue of DUN99845.

IK-862 is a selective inhibitor of TACE (ADAM17).

INCB3619 is a selective and potent inhibitor of ADAM with antitumour effects, inhibiting ADAM10, ADAM17, MMP12 and MMP15.

JG26 is a potent inhibitor of ADAM17, which can inhibit ADAM8, ADAM17, ADAM10 and MMP-12, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM, respectively, and can be used to study the immune system of the body.

K-111 (BM-170744) is an orally available peroxisome proliferator-activated receptor (PPAR)-alpha agonist and insulin enhancer for the study of obesity-type diabetes mellitus and the metabolic syndrome.

diABZI STING agonist-1 (trihydrochloride) is a stimulator of interferon genes (STING) receptor agonist.

IEM 1754 2HBr (IEM 1754 dihydrobromide) is a selective AMPA/kainate receptor blockers for GluR1 and GluR3 with IC50 of 6 μM.

Rosolutamide (ALZ-003) is a curcumin analog, an orally active Nrf1 and Nrf2 activator.Rosolutamide modulates oxidative homeostasis, improves mitochondrial function and promotes autophagy, reduces mutant protein aggregation, and decreases intracellular/mitochondrial reactive oxygen species (ROS) levels.Rosolutamide has been used in the study of neurodegeneration such as spinal cerebellar ataxia and Huntington disease. neurodegenerative diseases such as Huntington's disease. Regulates oxidative homeostasis.